AKESO(HK:09926) China Post Securities·2025-07-07 09:45Industry Investment Rating - The industry investment rating is "Outperform" [2] Core Views - The report highlights that the PD-(L)1/VEGF bispecific antibody business development (BD) expectations are driving a sustained surge in the innovative drug market. AstraZeneca is in talks for a potential deal worth up to $15 billion with Summit Therapeutics for the PD-1/VEGF bispecific antibody AK112, indicating strong recognition from multinational corporations (MNCs) for this class of drugs [5][14] - The successful launch of Vuxin Qibai monoclonal antibody marks a harvest period for innovative drugs in the gout field, with the market for anti-gout drugs in China expected to grow from 2.2 billion yuan in 2024 to over 10 billion yuan by 2030 [6][32] - The pharmaceutical and biotechnology sector has seen a 3.64% increase, outperforming the CSI 300 index by 2.1 percentage points, ranking 4th among 31 sub-industries [7][41] Summary by Sections Weekly Insights - The report discusses the ongoing excitement in the innovative drug market driven by the PD-(L)1/VEGF bispecific antibody BD expectations and the successful market entry of Vuxin Qibai monoclonal antibody [5][6][14] Subsector Performance - The pharmaceutical and biotechnology sector rose by 3.64%, with other biopharmaceuticals showing the highest increase of 8.28%. The medical device sector experienced the largest decline at 0.21% [7][41][44] Recommended and Benefiting Stocks - Recommended stocks include: - Innovative drugs: Xinda Biopharma, Kangfang Biopharma, and others - Medical devices: Yingke Medical, Maipu Medical, and others - Benefiting stocks: Innovative drugs in H-shares and A-shares, including Zai Lab, Yifang Biopharma, and others [8][40][51]